Scinai swings to FY26 H1 net income of USD 1.57 million; operating loss widens to USD 4.61 million

Reuters2026/08/24 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Scinai Immunotherapeutics posted revenue of USD 949,000, up 22.77% for the six months ended June 30, 2026.
Operating loss widened to USD 4.61 million from USD 3.76 million a year earlier.
Net income swung to USD 1.57 million, driven by a USD 6.4 million bargain purchase gain from the Recipharm Israel acquisition.
Committed customer orders reached about USD 3.1 million as of Aug. 16, with about USD 2.1 million invoiced.
Received about USD 650,000 in cash payments and advances for an expanded U.S. clinical manufacturing and CMC program; targeting about USD 5 million CDMO revenue in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240700PR_NEWS_USPR_____LN31850) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Scinai swings to FY26 H1 net income of USD 1.57 million; operating loss widens to USD 4.61 million

You may also like

Crypto prices